CVM

CEL-SCI Corporation 10-K Summary

Business Context and Reporting Period

Company: CEL-SCI Corporation (CEL-SCI)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 1998
Business Overview: CEL-SCI is a biopharmaceutical company focused on the research and development of immunotherapies and vaccines. Its primary pipeline includes MULTIKINE (a cytokine cocktail for cancer treatment), HGP-30 (an AIDS vaccine), and LEAPS (a T-cell modulation technology). The Company has no commercial product sales and relies on investment income and capital raises to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Investment income increased significantly to $728,421 in 1998 from $386,547 in 1997, driven by interest accrued on investments from the Series D Preferred Stock sale.
• Expense Reduction: Research and Development (R&D) expenses decreased by approximately 36% to $3.83 million. Management attributes this to the fact that major acquisition costs for MULTIKINE and LEAPS technologies were expensed in fiscal 1997.
• Administrative Increase: General and Administrative (G&A) expenses rose to $3.11 million, primarily due to increased staffing and a $587,377 charge for stock options granted to non-employees.
• Liquidity Position: Total assets more than doubled from 1997 to 1998, largely due to the accumulation of investment securities ($9.68 million) following capital raises. However, cash on hand decreased by approximately $695,000 during the year.

Guidance, Outlook, and Risks

• Outlook: Management expects to spend between $3.5 million and $4.0 million on R&D and clinical trials in fiscal 1999. The Company plans to fund this using existing financial resources.
• Clinical Progress:
  • MULTIKINE: Ongoing studies in Israel, Canada, and the U.S. for head and neck cancer and prostate cancer. Early data showed tumor regression in some patients.
  • HGP-30 (AIDS Vaccine): Phase II trials ongoing in the Netherlands. An improved version (HGP-30W) showed broader recognition of HIV subtypes.
  • LEAPS: Formulation studies for LEAPS 101 (HIV) are underway, with human testing projected for the second half of 1999.
• Risks and Contingencies:
  • Regulatory Approval: No products have received FDA approval. Clinical trials conducted outside the U.S. may not be accepted by the FDA, potentially delaying commercialization.
  • Liquidity: The Company has no revenue from product sales and is dependent on future equity or debt financing to continue operations. There is no assurance such financing will be available.
  • Manufacturing: Reliance on a third-party manufacturer for MULTIKINE; switching suppliers could take 6-10 months.
  • Year 2000: The Company is modifying computer systems for Y2K compliance, expecting completion by early 1999 with insignificant costs.

Investor Verification Checklist

• Cash Burn Rate: Verify if the current cash balance ($2.8M) and investment portfolio are sufficient to cover the projected $3.5M-$4.0M R&D spend for fiscal 1999 without immediate dilution.
• Regulatory Path: Confirm the status of FDA acceptance for clinical data generated in Israel, Canada, and the Netherlands, as this is critical for U.S. market entry.
• Related Party Transactions: Review the history of transactions involving Maximilian de Clara (President) and Sittona Company regarding the acquisition of MULTIKINE rights.
• Stock Dilution: Assess the impact of outstanding warrants and convertible preferred stock (Series D) on future share count and earnings per share.
• Manufacturing Dependency: Evaluate the risk associated with the single-source manufacturing agreement for MULTIKINE expiring in 2000.